The Taiwan-ADNI workflow toward integrating plasma p-tau217 into prediction models for the risk of Alzheimer's disease and tau burden
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Plasma p-tau217 accurately identifies Alzheimer's disease patients with low/intermediate tau burden. A two-step workflow using p-tau217 and amyloid PET can streamline diagnosis for anti-amyloid therapy eligibility.
Area Of Science
- Neurology
- Biomarker Discovery
- Alzheimer's Disease Diagnostics
Background
- Emerging anti-amyloid therapies necessitate precise Alzheimer's disease (AD) diagnosis.
- Plasma biomarkers, particularly phosphorylated tau 217 (p-tau217), show promise for AD diagnosis.
- Accurate identification of amyloid-positive individuals with varying tau burden is crucial.
Purpose Of The Study
- To propose and validate a workflow for identifying amyloid-positive individuals with low/intermediate tau burden.
- To evaluate the diagnostic potential of plasma biomarkers for Alzheimer's disease.
- To assess the utility of p-tau217 in predicting tau burden in amyloid-positive patients.
Main Methods
- Assessed 361 participants across the AD and non-AD continuum.
- Measured plasma p-tau217, p-tau181, amyloid beta (Aβ)42/40 ratio, neurofilament light chain, and glial fibrillary acidic protein.
- Utilized [18F]Florzolotau PET for tau burden quantification and amyloid PET for amyloid status.
Main Results
- Plasma p-tau217 demonstrated the highest consistency with amyloid PET results (AUC = 0.94).
- A p-tau217 cutoff could reduce confirmatory amyloid PET scans by 57.5%.
- In amyloid PET-positive cases, p-tau217 combined with clinical parameters best predicted low/intermediate tau burden.
Conclusions
- A two-step workflow integrating p-tau217 and amyloid PET accurately classifies AD patients with low/intermediate tau burden.
- Plasma p-tau217 is a reliable predictor of amyloid positivity and tau burden.
- This workflow can aid in selecting suitable candidates for anti-amyloid therapies.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
